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Calcitonin Gene-Related Peptide Decreases Expression of
HLA-DR and CD86 by Human Dendritic Cells and Dampens
Dendritic Cell-Driven T Cell-Proliferative Responses Via the
Type I Calcitonin Gene-Related Peptide Receptor1
John A. Carucci,2* Ralf Ignatius, 3* Yang Wei,* Aaron M. Cypess,† David A. Schaer,*
Melissa Pope,* Ralph M. Steinman,* and Svetlana Mojsov4*
These studies were performed to establish whether functional receptors for calcitonin gene-related peptide (CGRP) are present
on human dendritic cells (DCs) and to investigate potential immunomodulatory effects of CGRP on DCs other than Langerhans
cells. Reverse transcriptase-PCR revealed expression of mRNA for a type 1 CGRP receptor by mature and immature blood-
derived DCs. Sequence analysis confirmed the identity of the type 1 CGRP receptor (CGRP-R1). Addition of CGRP (1027 M) to
mature and immature DCs resulted in mobilization of intracellular calcium. Treatment of immature DCs with CGRP (1027 M),
before and after maturation in monocyte-conditioned medium, resulted in decreased cell surface expression of HLA-DR MHC
class II and the costimulatory molecule, CD86. Treatment of immature DCs with CGRP (1027 M) also resulted in decreased
expression of CD86, but expression of HLA-DR was unchanged. When CGRP-treated mature DCs were used to stimulate allo-
geneic T cells, proliferative responses were dampened (;50%), especially at low DC:T cell ratios (1:360). This effect was not
observed with CGRP-treated, immature DCs. In contrast, CGRP-treated mature or immature DCs were no less efficient than
untreated DCs in driving syngeneic T cell-proliferative responses to staphylococcal enterotoxin B. We conclude that mature and
immature DCs express type 1 CGRP receptors and that signaling through these receptors may dampen mature DC-driven T cell
proliferation most likely via down-regulation of CD86 and HLA-DR. The Journal of Immunology,2000, 164: 3494–3499.
N europeptides, including calcitonin gene-related peptide(CGRP),5 can regulate immunity (1–3). CGRP in addi-tion dilates cerebral, coronary, and peripheral vessels;
regulates glucose metabolism; exhibits potent cardiotonic effects;
and may also play a role in migraine-associated neurogenic in-
flammation due to its localization in the trigeminal ganglia (4).
CGRP interacts with specific G-protein-coupled receptors and is
synthesized and released by capsaicin-sensitive sensory nerves (4).
Langerhans cells (LCs) are bone marrow-derived epidermal cells
that are committed to mature into dendritic cells (DCs) (5). Hosoi
et al. (6, 16) demonstrated modulation of epidermal LCs by nerves
that secrete CGRP. Torii et al. (7) described CGRP-mediated aug-
mentation of LPS-induced IL-10 mRNA and suppression of LPS
and GM-CSF-induced IL-12 mRNA in macrophages and the epi-
dermal LC-like cell line XS52.
Although neuropeptides can influence many cell types in the
immune system including LCs, their effects on human blood-de-
rived DCs have not been extensively characterized. These profes-
sional APCs express the two signals (8) required by T cells: one
signal consisting of processed Ag presented on MHC class I or II;
and second signals for T cell binding and activation via such mol-
ecules as ICAM-1 (CD54), LFAs (CD2, CD11a, CD58), and B7s
(CD80, CD86). DCs derived from monocytes exposed to IL-4 and
GM-CSF express MHC class II and CD86 but revert to a macro-
phage phenotype if GM-CSF or IL-4 is withdrawn (9). Further
culture with monocyte conditioned medium (MCM) yields fully
mature DCs. We show that immature and mature DCs possess type
1 CGRP receptors and that treatment with CGRP during the mat-
uration phase can dampen DC stimulation of T cells.
Materials and Methods
Culture medium
We used RPMI 1640 (Cellgro, Fisher Scientific, Springfield, NJ), supple-
mented with 2 mML-glutamine (Life Technologies, Grand Island, NY), 50
mM 2-ME (Sigma, St. Louis, MO), 10 mM HEPES (Life Technologies),
penicillin (100 U/ml)-streptomycin (100mg/ml) (Gemini Bio Products,
Calabrasas, CA), and 1% human plasma (heparinized).
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Recombinant human GM-CSF was purchased from Immunex (Seattle,
WA), and recombinant human IL-4 was purchased from R&D
(Minneapolis, MN).
Monocyte-conditioned medium (MCM)
IgG-coated bacteriologic plates (100 mm, Falcon, Lincoln Park, NY) were
prepared immediately before use by addition of 4 ml humang-globulin (10
mg/ml, Cappel Laboratories, Organon Teknika, Westchester, PA) for 3
min. Plates were washed three times with PBS before use. Peripheral blood
was obtained from buffy coats purchased from the New York Blood Center
(New York, NY). PBMCs were isolated by sedimentation in Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden). T cell-depleted (eryth-
rocyte rosette (ER)2) fractions were prepared by rosetting with neuramin-
idase-treated sheep RBC as described previously (10). T cell-depleted
(ER2) cells (53 107) or 9 3 107 PBMCs were cultured on IgG-coated
plates for 1 h at 37°C. Nonadherent cells were washed off with gentle
aspiration. The IgG-adherent cells were cultured with 10 ml fresh medium
at 37°C for 24 h. The medium was collected and frozen at220°C
before use.
Monoclonal Abs
mAbs to the following Ags were used: HLA-DR; CD3; CD14; CD20;
CD25 (PE conjugate, Becton Dickinson, Mountain View, CA); CD83
(IgG1, unlabeled or PE conjugate, Coulter, Miami, FL); and CD86 (PE
conjugate, PharMingen, San Diego, CA). Cell populations were pheno-
typed with these mAbs using a FACScan (Becton Dickson Immunocyto-
metry Systems, San Jose, CA).
Generation of DCs from human blood
Peripheral blood was obtained from normal human donors in heparinized
syringes or from buffy coats purchased from the New York Blood Center.
T cell-enriched (ER1) or T cell-depleted (ER2) fractions from PBMCs
were prepared by rosetting with neuraminidase-treated sheep RBC as de-
scribed (10). ER2cells (2.53 106/well) were plated in each well of a
six-well plate (Falcon). Alternatively, adherent monocytes were derived by
plating 8 3 106 PBMCs/well in 3 ml culture medium for 1 h at 37°C.
Nonadherent cells were removed, and adherent cells washed with warm
RPMI. GM-CSF (1000 U/ml) and recombinant human IL-4 (100 U/ml)
were added to the ER2or adherent monocytes on day 0 of culture and
replenished on days 2, 4, and 6 by removal of 0.3 ml medium followed by
addition of 0.5 ml medium with cytokines. To generate mature DCs, cul-
tures were supplemented with MCM (50% v/v) on day 7. To generate
immature DCs, cultures were supplemented with cytokines on day 8 but
were not supplemented with MCM.
Purification of DCs
In all experiments, CD14-negative, immature, and mature DCs were puri-
fied by negative selection by incubation with anti-CD2 and anti-CD19
Dynabeads (Dynal, Oslo, Norway) per manufacturer’s instructions. After
two cycles of separation as described (11), purity was.99% and was
confirmed by FACS analysis.
Generation of T cells
PBMCs from heparinized blood from normal human donors or from buffy
coats were isolated by sedimentation in Ficoll-Hypaque as described for
generation of DCs. T cell-enriched (ER1) fractions were prepared by ro-
setting with neuraminidase-treated sheep RBC (10). Alternatively, T cells
were purified from nonadherent fractions by negative selection by incuba-
tion with Dynabeads coated with anti-HLA-DR according to the manufac-
turer’s instructions. Purity was confirmed by FACS analysis.
Neuropeptides and neuropeptide treatment
CGRP and CGRP type 1 receptor antagonist, CGR8–37, were purchased
from Phoenix Pharmaceuticals (Belmont, CA), and CGRP type 2 receptor
agonist, diacetoamidomethylcysteine CGRP (CYS (ACM 2, 7) CGRP) was
purchased from Sigma. The neuropeptide treatment protocol was a modi-
fication of the one described by Fox et al. (12). Immature DCs, after 7 days
of culture with IL-4 (100 U/ml) and GM-CSF (1000 U/ml), were cultured
with CGRP (1027 M) for 2 h at 37°C. Then cells were cultured for 2
additional days in medium supplemented with MCM and CGRP. As men-
tioned earlier, addition of MCM to the culture media for 2 days promotes
DC maturation. We refer to this cell population as CGRP-treated, mature
DCs. In parallel plates, DCs were cultured for additional 2 days with
CGRP, but without addition of MCM in the culture medium. Under these
conditions, DCs do not mature and remain as immature DCs. We refer to
this cell population as CGRP-treated, immature DCs. At day 9, CGRP-
treated, mature DCs and CGRP-treated, immature DCs were cultured again
with CGRP (1027 M) for 2 h at 37°C and washed twice before phenotypic
analysis and functional assays.
Allogeneic mixed leukocyte reactions
To test for allogeneic T cell-stimulatory function, 50–5000 purified CGRP-
treated or untreated, mature or immature DCs were added as stimulators for
2 3 105 allogeneic T cells in 96-well flat-bottom plates (Costar, Cam-
bridge, MA) for 5 days at 37°C. Each combination was set up in triplicate,
and proliferation was determined on day 5 by measuring the uptake of
[3H]TdR (4mCi/ml) during the final 8 h of coculture. Results are expressed
as the mean cpm incorporated from triplicate wells (mean cpm). In some
experiments, CGRP (1027 M in each well) was added to cocultures on days
0, 2, and 4.
Staphylococcal enterotoxin B (SEB) assay
As another assay for DC presenting function, 300–10,000 CGRP-treated or
untreated, mature or immature, purified DCs were added to 13 105 T cells
with 5 ng/ml SEB (Toxin Technology, Sarasota, FL) in 96-well flat-bottom
plates and cultured for 3 days at 37°C. Each combination was set up in
triplicate, and proliferation was determined on day 3 using [3H]TdR (4
mCi/ml) uptake during the final 8 h (mean cpm). In some experiments,
CGRP (1027 M in each well) was added to cocultures on days 0 and 2.
Assay for intracellular calcium
Mature or immature, purified DCs (2–83 106) were collected in 17-3
20-mm conical tubes (Falcon), pelleted at 2000 rpm for 2 min, washed
twice with EBSS-H (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM
NaH2PO4, 26 mM HEPES, 5.6 mM glucose, 0.1% w/v BSA, 2 mM CaCl2),
and resuspended in 1 ml EBSS-H at 1–43 106 cells/ml. The fluorophore
fluo-3-acetoxymethyl ester (fluo-3-AM) (Molecular Probes, Eugene, OR)
was added to 2mM, and the DCs were incubated for 60–75 min at room
temperature on a nutator. The fluo-3-AM-loaded DCs were pelleted and
resuspended in EBSS-H, washed again, and incubated in EBSS-H for
30–45 min. The DCs were pelleted and transferred to cuvettes at 2–43
106 cells/ml, and the fluorescence due to intracellular calcium was mea-
sured at room temperature in a Hitachi F-2000 fluorescence spectropho-
tometer using excitation and emission wavelengths of 505 and 525 nm,
respectively.
RT-PCR for detection of CGRP-R1 transcripts
Total RNA from 1–23 106 purified mature or immature DCs was ex-
tracted in 2 ml RNAzol (Tel-Test, Friendswood, TX) mixed with 0.2 ml
chloroform and centrifuged at 12,0003 g for 15 min. The aqueous phase
was transferred to a fresh tube, isopropanol was added to precipitate the
RNA, and the pellet was dissolved in 20ml double-distilled H2O and stored
at220°C. First-strand cDNA was reverse transcribed from 5g total RNA
in a 20-ml reaction volume in 20 mM Tris-HCl; 50 mM KCl; 2.5 mM
MgCl2; 10 mM DTT; 500 nM oligo(dT); 500mM each dATP, dCTP,
dGTP, dTTP; and 200 U Super Script II RT (Life Technologies, Gaithers-
burg, MD) for 50 min at 42°C. Twoml of the 20ml of RT reaction mixture
were PCR amplified. Primers for human CGRP-R1 were synthesized based
on a published sequence (13). The sense primer 59-TCT GGT TCT CTT
GCC TTT TTT TAT G-39corresponded to nucleotides 581–605, and the
antisense primer 59-GTC CAT GTT CTG TTG CTT GCT G-39was com-
plementary to nucleotides 898–919. Thirty cycles of PCR were run at 94°C
for 1 min, 56°C for 1 min, and 72°C for 1 min with 2.5 UTaqpolymerase
(Perkin-Elmer, Norwalk, CT).
Automated DNA sequencing
This was done byTaqFS dye terminator cycle sequencing using a Model 377
stretch sequencer (Perkin-Elmer/Applied Biosystems, Foster City, CA) (14).
Results
Immature and mature DCs express CGRP-R1 mRNA.
Because immunomodulatory effects of CGRP on LCs had been
described, we set out to identify CGRP receptors on DCs derived
from human PBMCs and then study their immunoregulatory po-
tential. Total RNA was isolated from purified blood-derived, ma-
ture, and immature DCs. Results of RT-PCR experiments indi-
cated that mRNA specific for CGRP type 1 receptor (CGRP-R1)
















(705 bp) was expressed in mature and immature DCs (Fig. 1).
Sequence analysis confirmed 98 and 99% identity with the human
CGRP-R1, as recorded in GenBank, for mature and immature
DCs, respectively.
CGRP triggers calcium flux in immature and mature DCs
To determine the functional potential of CGRP-R1 on DCs, we
measured the ability of CGRP to trigger calcium fluxes in mature
and immature cells. The DCs were loaded with fluo-3 AM, a dye
that exhibits increased fluorescence in the presence of calcium.
When either mature or immature, fluo-3-AM-loaded DCs were
treated with CGRP (1027 M), intracellular calcium mobilization
was noted as determined by fluorometry (Fig. 2). Mobilization of
intracellular calcium was abrogated by the presence of equimolar
concentrations of CGRP8–37, a CGRP-R1 antagonist, whereas cal-
cium flux was not triggered by diacetoamidomethylcysteine CGRP
(CYS (ACM 2, 7) CGRP), an agonist for the type 2 CGRP receptor
(CGRP-R2) (data not shown). Mobilization of intracellular cal-
cium by CGRP confirmed the functionality of the CGRP-R1 re-
ceptor on both mature and immature DCs.
Decreased surface expression of CD86 and HLA-DR on CGRP-
treated, mature DCs
As shown previously, CD25 and CD83 are expressed on mature
DCs, whereas the levels of the MHC class II molecule, HLA-DR,
and the costimulatory molecule, CD86, are increased (9). Previous
studies indicated that CGRP suppressed CD86 in the murine, LC-
like, XS52 cells (6), so we conducted similar studies on human
DCs, as a model for the in vivo situation in which DCs are exposed
to neurogenic stimuli before or concomitant with the exposure to
Ag. Treatment of purified DCs with CGRP (1027 M) for 2 h before
and during culture with MCM, and for an additional 2 h after the
MCM-induced maturation phase, yielded CGRP-treated, mature
DCs and resulted in decreased expression of CD86 and HLA-DR
(Fig. 3). Expression of CD25, thea subunit of the IL-2 receptor,
FIGURE 3. Surface expression of CD86 and HLA-DR are decreased in
CGRP-treated, mature DCs. Pure immature DCs were treated with CGRP
(1027 M) for 2 h at 37°C before and after 2 days culture with MCM to yield
CGRP-treated, pure mature DCs. HLA-DR, CD14, CD25, CD83, and
CD86 were assessed on a FACScan.
FIGURE 1. Immature and mature human DCs express CGRP-R1
mRNA. DCs were generated by culturing ER2or adherent PBMCs with
GM-CSF and IL-4 for 7 days, and then cultured 2 more days in MCM, to
generate mature DCs, or with GM-CSF/IL-4 only to form immature DCs.
RT-PCR was done on RNA from purified immature and mature DCs.Lane
1, markers;Lane 2,CGRP type 1 receptor in immature DCs (705 bp);Lane
3, CGRP type 1 receptor in mature DCs (705 bp). Actin is at 249 bp.
FIGURE 2. CGRP triggers calcium flux in immature and mature DCs.
Pure immature and mature DCs were derived from human monocytes (Ma-
terials and Methods). DCs were treated with CGRP (1027 M), and mobi-
lization of intracellular calcium was measured. Data, from one of three
representative experiments, are expressed as fluorescence units.
















and CD83, a maturation marker, were unchanged by CGRP treat-
ment. Treatment of immature DCs with CGRP (1027 M) subse-
quently cultured with GM-CSF and IL-4 but without MCM,
yielded CGRP-treated, immature DCs with decreased expression
of CD86 but unchanged expression of HLA-DR (not shown).
CD25 and CD83 expression on immature DCs remained negative
after CGRP treatment. Decreased expression of CD86 and
HLA-DR was observed with DCs from 60% of the buffy coats and
blood donors we studied. In all cases in which regulation was
observed, the changes in expression of HLA-DR and CD86 oc-
curred conjointly. In the case of CGRP-treated, mature DCs, these
phenotypic changes correlated with diminished induction of allo-
geneic T cell proliferation.
Decreased allogeneic T cell stimulation by CGRP-treated,
mature DCs
The down-regulation of CD86 on CGRP-treated, mature, and im-
mature DCs suggested that CGRP treatment might modulate their
Ag-presenting capability. This was investigated using the alloge-
neic MLR assay. Mature DCs vigorously stimulate allogeneic T
cells and at low DC:T cell ratios (9), whereas previous studies
revealed a decrease in allogeneic T cell stimulation by CGRP-
treated LCs (6). Therefore, purified, CGRP-treated or untreated,
mature or immature DCs were used to stimulate allogeneic T cells
in the MLR assay. The proliferative responses were lower than
those induced by untreated, mature DCs (25–50%), especially at
low DC:T cell ratios (1:360 in Fig. 4). Addition of CGRP (1027
M) to DC:T cell cocultures on days 0, 2, and 4 of the MLR assay
had no additional effect on T cell-proliferative responses. In con-
trast, allogeneic T cell-proliferative responses driven by CGRP-
treated, immature DCs were not different from those driven by
untreated, immature DCs.
CGRP treatment of DCs does not affect T lymphocyte responses
to SEB
Finally, we examined presentation in a superantigen (SEB) system
that is less sensitive to subtle changes in surface expression of
HLA-DR. Varying numbers of purified, CGRP-treated or un-
treated, mature or immature DCs were cultured with syngeneic T
cells and SEB, for 3 days, to determine whether CGRP treatment
might decrease this DC-driven response. However, T cell-prolif-
erative responses were unchanged (Fig. 5). Further addition of
FIGURE 4. CGRP treatment of DCs decreases their allogeneic stimu-
latory capacity.A, Mature DCs.B, Immature DCs. DCs were generated as
described inMaterials and Methods. Varying numbers of CGRP-treated or
untreated, pure mature or immature DCs were cocultured with allogeneic
T cells for 5 days, and proliferation was determined by tritiated thymidine
uptake. In some experiments, additional CGRP (1027 M in each well) was
added at days 0, 2, and 4 of coculture. Data are from one of three exper-
iments with similar results and are mean [3H]TdR cpm3 1023 6 SEM.■,
Control DCs;M, CGRP-treated DCs;F, control DCs with CGRP added
during coculture;E, CGRP-treated DCs with CGRP added during
coculture.
FIGURE 5. CGRP treatment of DCs does not affect their ability to stim-
ulate T lymphocyte responses to SEB. A, Mature DCs.B, Immature DCs.
Varying numbers of CGRP-treated or untreated, pure mature or immature
DCs were cocultured with syngeneic T cells and SEB for 3 days, and
proliferation was determined by tritiated thymidine uptake. Data are from
one of three experiments with similar results and are expressed as mean
[3H]TdR cpm3 1023 6 SEM.f, Control DCs;u, CGRP-treated DCs.
















CGRP (1027 M) to the cocultures on days 0 and 2 did not affect the
response to SEB (data not shown).
Discussion
Several points have become apparent in these studies: 1) mature
and immature DCs express mRNA specific for CGRP-R1; 2) treat-
ment of mature and immature DCs with CGRP leads to the mo-
bilization of intracellular calcium; 3) cell surface expression of
CD86 and HLA-DR are decreased on “CGRP-treated, mature
DCs”; 4) expression of CD86, but not HLA-DR, is decreased on
CGRP-treated, immature DCs; and 5) CGRP-treated, mature DCs
are less effective at driving allogeneic T cell proliferation than
untreated DCs but are unaffected in stimulating syngeneic T cell
responses to SEB.
Our results extend the findings that some neuropeptides may
regulate immune responses (15). Neuropeptides, including CGRP,
pituitary adenylate cyclase-activating peptide, vasoactive intestinal
peptide, and substance P, can regulate the function of B cells, T
cells, and macrophages (1). The interaction of LCs and neu-
ropeptides, in particular CGRP, has been described (3). Hosoi et
al. (16) demonstrated that LCs often lie in apposition with epi-
dermal nerves containing CGRP. Also CGRP is required for
UVB-mediated suppression of contact hypersensitivity (CH)
(17, 18). Other studies support the potential suppression of
delayed-type hypersensitivity as well as CH by CGRP (19).
Finally, Fox et al. (12) reported that treatment of human mono-
cytes with CGRP for 2 h decreased their presentation of tetanus
toxoid.
The expression of CGRP-R1-specific mRNA (Fig. 1) by DCs
alludes to the potential for functional regulation of DCs by neu-
ropeptides. At least two subtypes of CGRP receptors have been
identified, termed CGRP-R1 and CGRP-R2 (20). Sequence iden-
tity with human CGRP-R1 supports the presence of the type 1
receptor on human blood-derived DCs, consistent with other data
of CGRP-R1 on LCs (21).
CGRP-R1 mobilizes intracellularcalcium in human DCs (Fig. 2).
The CGRP receptor is a member of a superfamily of transmembrane
receptor proteins. On ligand binding, the receptor couples to a mem-
brane-associated heterotrimeric G protein that initiates signaling path-
ways, ultimately leading to increased intracellular calcium (22). The
inhibition of calcium fluxes by the CGRP-R1 antagonist and the lack
of a calcium flux to CYS(ACM 2, 7) CGRP, a CGRP R-2 agonist,
further supports the presence of a functional CGRP R1 on DCs.
The identity of specific G protein subunits involved with CGRP-
mediated signaling in DCs remains to be determined.
Dampening of DC-driven immune responses by CGRP may in-
volve regulation of costimulatory molecules, alterations in cyto-
kine induction, or direct effects on Ag uptake. We observed a de-
creased expression of CD86 and HLA-DR by CGRP-treated,
mature DCs (Fig. 3) but only a decrease in CD86 in CGRP-treated,
immature DCs. Because the stimulatory activity for allogeneic T
cells was decreased only for mature DCs (Fig. 4), the down-reg-
ulation of HLA-DR may be more significant. CGRP also did not
reduce DC-driven T cell proliferation to SEB, a phenomenon that
is less susceptible to subtle down-regulation of HLA-DR (23), sup-
porting a role for HLA-DR down-regulation in the dampening of
allogeneic T cell proliferation to CGRP-treated, mature DCs.
As stated earlier, the phenomenon of phenotypic regulation was
observed in only 60% of blood donors. The reasons for this are not
clear and may involve differences in the level of expression of
CGRP-R1 on DCs or the presence of defective receptors in some
individuals. However, in all cases in which regulation was ob-
served, the changes in expression of HLA-DR and CD86 occurred
in concert, and, in CGRP-treated, mature DCs, phenotypic changes
correlated with reduced allogeneic T cell stimulation.
Suppression of CD86 on human monocytes by CGRP has been
described and has been reported to involve IL-10 (12). Other stud-
ies have demonstrated CGRP-mediated induction of IL-10 and
suppression of IL-12 and CD86 in the epidermal LC-like cell line
XS52 (7). The dampened DC function that we observed still needs
to be addressed at the levels of these cytokines and Ag uptake.
Dampened immune responses in another system has been sug-
gested by Khachatryan et al., who showed that CGRP expression
in pancreaticb cells suppresses development of diabetes in nono-
bese diabetic mice (24).
We considered the idea that CGRP could have a direct effect on
T cells. CGRP potentiates T cell proliferation in the presence of
IFN-g-treated, class II-bearing, intestinal smooth muscle cells (25)
but suppresses mitogen-stimulated murine T cells (26). In our stud-
ies, addition of CGRP (1027 M) to DC:T cell cocultures had no
effect on DC-driven allogeneic T cell proliferation or responses to
SEB (Figs. 4 and 5). The expression of CGRP-R1 mRNA by im-
mature and mature DCs, coupled with effects of CGRP on intra-
cellular calcium, HLA-DR, and CD86, suggests that CGRP acts on
DCs directly.
On the basis of previous and current findings, we speculate that
the release of neuropeptides in the face of inflammatory stimuli,
including certain inflammatory skin disorders, can suppress APCs
including DCs. The cellular mechanisms involved in regulation of
CH induction by UV radiation, especially the role of LCs, have
been studied (17–19, 27). The potential therapeutic effects of UV
radiation in inflammatory disorders, including atopic dermatitis
and psoriasis, are also described (28). Because CGRP is required
for the suppression of CH by UVB (18, 19), CGRP may influence
responses to phototherapy. Accordingly, selective activation of
CGRP-R1 on DCs might prove useful in the treatment of inflam-
matory skin disorders.
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